This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety Study of GS-5806 to Treat Respiratory Syncytial Virus (RSV)

This study has been withdrawn prior to enrollment.
Information provided by (Responsible Party):
Gilead Sciences Identifier:
First received: February 20, 2013
Last updated: October 24, 2013
Last verified: October 2013
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetics of GS-5806 in hospitalized infants with RSV.

Condition Intervention Phase
Respiratory Syncytial Virus Infections Drug: GS-5806 Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single-Dose Ranging Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GS-5806 in Subjects < 24 Months of Age Hospitalized for Respiratory Syncytial Virus (RSV) Related Respiratory Infection

Resource links provided by NLM:

Further study details as provided by Gilead Sciences:

Primary Outcome Measures:
  • Safety and tolerability [ Time Frame: 10 days from subject randomization to study drug ]
    Safety and tolerability will be assessed by evaluating AE's, laboratory abnormalities and vital sign measurements.

Secondary Outcome Measures:
  • Pharmacokinetics effects of GS-5806 [ Time Frame: 10 days from subject randomization to study drug ]
    Evaluation of GS-5806 on viral load related and symptom related endpoints.

Enrollment: 0
Study Start Date: May 2013
Estimated Study Completion Date: August 2013
Estimated Primary Completion Date: August 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GS-5806
Single dose, oral liquid, .5 mL/kg
Drug: GS-5806
Single dose, oral liquid, .5 mL/kg
Placebo Comparator: Placebo
Single dose, oral liquid, .5 mL/kg
Drug: Placebo
Single dose, oral liquid, .5 mL/kg


Ages Eligible for Study:   up to 24 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • <24 months of age
  • Diagnosis of Respiratory Syncytial Virus (RSV) within 48 hours of screening

Exclusion Criteria:

  • Chronic or congenital heart disease
  • Required ventilation or admission to any pediatric Intensive Care Unit
  • Inadequate organ function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01797419

Australia, Victoria
Geelong Hospital
Geelong, Victoria, Australia, 3220
Monash Medical Center
Clayton, Australia
Queensland Children's Medical Research Unit
Herston, Australia
Royal Hobart Hospital
Hobart, Australia
Women's and Children's Hospital Adelaide
North Adelaide, Australia
Royal Children's Hospital
Parkville, Australia
Sydney Children's Hospital
Randwick, Australia
Princess Margaret Hospital for Children
Subiaco, Australia
Westmead Children's Hospital
Westmead, Australia
Sponsors and Collaborators
Gilead Sciences
Principal Investigator: Peter Sly, MD Queensland Children's Medical Research Unit, Herston, AUS
  More Information

Responsible Party: Gilead Sciences Identifier: NCT01797419     History of Changes
Other Study ID Numbers: GS-US-218-0104
Study First Received: February 20, 2013
Last Updated: October 24, 2013

Keywords provided by Gilead Sciences:

Additional relevant MeSH terms:
Virus Diseases
Respiratory Syncytial Virus Infections
Pneumovirus Infections
Paramyxoviridae Infections
Mononegavirales Infections
RNA Virus Infections processed this record on September 21, 2017